NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the transaction, the insider now owns 11,150,461 shares of the company's stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Nap B.V. Forgrowth also recently made the following trade(s):
- On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.
- On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.
NewAmsterdam Pharma Trading Up 0.1 %
Shares of NAMS opened at $24.71 on Tuesday. The stock has a fifty day moving average price of $20.67 and a two-hundred day moving average price of $18.75. NewAmsterdam Pharma has a 52-week low of $10.12 and a 52-week high of $27.29.
Institutional Inflows and Outflows
Musk threatens Liberal’s fake “energy crisis”
From Porter & Company | Ad
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X.
And people are slowly starting to wake up to the Deep State’s lies.
To get the full details on the fake “energy crisis” of America, watch this now
A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after acquiring an additional 1,399 shares in the last quarter. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma during the second quarter worth approximately $38,000. Quarry LP grew its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC increased its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Finally, Bellevue Group AG bought a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $128,000. 89.89% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
NAMS has been the subject of a number of recent research reports. Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Scotiabank lifted their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $36.20.
Check Out Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
